FDA approves Unicycive's Oxylanthanum carbonate?

Analysis

The original FDA rejection was about manufacturing paperwork, not safety or efficacy. That's the most survivable kind of setback a drug can face — the science was never in question, just the factory docs. Oxylanthanum carbonate isn't a moonshot. Phosphate binders for dialysis patients are a proven drug class, and regulators understand exactly what they're looking at. That familiarity shortens the review conversation considerably. The PDUFA date lands June 29, and the market window runs to July 13 — that two-week buffer is doing real work here. FDA routinely slips a few days past target, and this structure actually absorbs that slippage without blowing up the bet. Two models did lean against approval, pointing to tight timelines and the general risk of last-minute snags. That's fair — manufacturing remediation at third-party vendors can generate repeat problems, and the window is genuinely narrow. But narrow isn't the same as impossible, and a CMC-only resubmission from a company that knew exactly what the FDA wanted is a meaningfully stronger position than a first-time applicant flying blind. I'd back Yes here because the fix was specific, the pathway is well understood, and the timeline cushion exists for exactly this kind of situation.